Physician profile
Andrew D Dick
NPI 1679570956
$14,636.86
in general payments reported to CMS, 2019-2025
62 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,986 · 2020: $3,863 · 2021: $2,794 · 2022: $2,012 · 2023: $1,172 · 2024: $1,264 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,805.97 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,870.91 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,510.54 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $1,442.04 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $1,062.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $969.30 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $925.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $924.01 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.62 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $423.44 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $405.85 | 2022-2025 | |
| Axsome Therapeutics, INC. | $320.45 | 2024-2025 | Auvelity, Sunosi |
| Astellas Pharma US INC | $317.00 | 2021-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $305.91 | 2019-2022 | Xyosted, Tlando |
| Allergan, INC. | $285.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $277.02 | 2019-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.